Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence

Acta Neuropsychiatrica

Volumn 16, Issue 5, 2004, Pages 233-238

  Kiefer, Falk ^a,b   Andersohn, F ^b   Otte, C ^b   Wolf, K ^b   Jahn, H ^b   Wiedemann, K ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Abstinence; Acamprosate; Alcoholism; Craving; Naltrexone; Treatment; Trial

Indexed keywords

ACAMPROSATE; NALTREXONE; PLACEBO;

AGITATION; ALCOHOLISM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVIDENCE BASED MEDICINE; FOLLOW UP; GENERAL PRACTITIONER; HEADACHE; HUMAN; INTERVIEW; LABORATORY TEST; MAJOR CLINICAL STUDY; NAUSEA; PREVENTIVE MEDICINE; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SELF REPORT; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VOMITING;

EID: 14644420875     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0924-2708.2004.00093.x     Document Type: Conference Paper

References (45)

1. KRANZLER HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol 2000;35:537-547.
2. RAMMES G, MAHAL B, PUTZKE J et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001;40:749-760.
3. ZEISE ML, KASPAROV S, CAPOGNA M, ZIEGLGANSBERGER W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 1993;231:47-52.
4. BOISMARE F, DAOUST M, MOORE N et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 1984;21:787-789.
5. GEWISS M, HEIDBREDER C, OPSOMER L, DURBIN P, DE WITTE P. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol 1991;26:129-137.
6. LITTLETON J. Acamprosate in alcohol dependence: how does it work? Addiction 1995;90:1179-1188.
7. LHUINTRE JP, DAOUST M, MOORE ND et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcohol dependent subjects. Lancet 1985;1:1014-1016.
8. LHUINTRE JP, MOORE N, TRAN G et al. Acamprosate appears to decrease alcohol intake in weaned alcohol dependent subjects. Alcohol Alcohol 1990;25:613-622.
9. PELC I, LE BON O, VERBANCK P, LEHNERT PH, OPSOMER L. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients; a placebo-controlled double-blind multi-centre study. In: NARANJO C, SELLERS EM, eds. Novel pharmacological interventions for alcoholism. New York: Springer-Verlag, 1992: 348-352.
10. LADEWIG D, KNECHT T, LEHER P, FENDL A. Acamprosate - a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 1993;50:182-188.
11. PAILLE FM, GUELFI JD, PERKINS AC, ROYER RJ, STERU L, PAROT P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995;30:239-247.
12. ROUSSAUX JP, HERS D, FERAUGE M. Does acamprosate diminish the appetite for alcohol in weaned alcohol dependent subjects? J Pharm Belg 1996;51:65-68.
13. WHITWORTH AB, FISCHER F, LESCH OM et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-1442.
14. SAss H, SOYKA M, MANN K, ZIEGLGANSBERGER W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53:673-680 [erratum appears in Arch Gen Psychiatry 1996;53 (12):1097].
15. SAss H, SOYKA M, MANN K, ZIEGLGANSBERGER W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53:673-680 [erratum appears in Arch Gen Psychiatry 1996;53 (12):1097].
16. PELC I, VERBANCK P, LE BON O, GAVRILOVIC M, LION K, LEHERT P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997;171:73-77.
17. GEERLINGS PJ, ANSOMS C, VAN DEN BRINK W. Acamprosate and prevention of relapse in alcohol dependent subjects. Eur Addict Res 1997;3:129-137.
18. POLDRUGO F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997;92:1537-1546.
19. BESSON J, AEBY F, KASAS A, LEHERT P, POTGIETER A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998;22:573-579.
20. TEMPESTA E, JANIRI L, BIGNAMINI A, CHABAC S, POTGIETER A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000;35:202-209.
21. CHICK J, HOWLETT H, MORGAN MY, RITSON B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000;35:176-187.
22. NAMKOONG K, LEE BO, LEE PG, CHOI MJ, LEE E. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003;38:135-141.
23. WILDE MI, WAGSTAFF AJ. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997;53:1038-1053 [Review].
24. VOLPICELLI JR, ALTERMAN AI, HAYASHIDA M, O'BRIEN CP. Naltrexone in the treatment of alcohol dependence [see comments]. Arch Gen Psychiatry 1992;49:876-880.
25. O'MALLEY SS, JAFFE AJ, CHANG G, SCHOTTENFELD RS, MEYER RE, ROUNSAVILLE B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992;49:881-887.
26. ANTON RF, MOAK DH, WAID LR, LATHAM P, MALCOLM R, DIAS JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcohol dependent subjects: results of a placebo-controlled trial. Am J Psychiatry 1999;156:1758-1764.
27. CHICK J, ANTON R, CHECINSKI K et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse, Alcohol Alcohol 2000;35:587-593.
28. LEE A, TAN S, LIM D et al. Naltrexone in the treatment of male alcohol dependent subjects - an effectiveness study in Singapore. Drug Alcohol Rev 2001;20:193-199.
29. OSLIN D, LIBERTO JG, O'BRIEN J, KROIS S, NORBECK J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence, Am J Geriatr Psychiatry 1997;5:324-332.
30. KRANZLER HR, MODESTO-LOWE V, VAN KIRK J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 2000;22:493-503.
31. MORRIS PL, HOPWOOD M, WHELAN G, GARDINER J, DRUMMOND E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001;96:1565-1573.
32. MONTI PM, ROHSENOW DJ, SWIFT RM et al. Naltrexone and cue exposure with coping and communication skills training for alcohol dependent subjects: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25:1634-1647.
33. KRYSTAL JH, CRAMER JA, KROL WF, KIRK GF, ROSENHECK RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001;345:1734-1739.
34. GASTPAR M, BONNET U, BONING J et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002;22:592-598.
35. CROOP RS, FAULKNER EB, LABRIOLA DF. The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry 1997;54:1130-1134.
36. KIEFER F, JAHN H, TARNASKE T et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60:92-99.
37. ANTON RF, MOAK DH, LATHAM P. The Obsessive Compulsive Drinking Scale. A self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1995;19:92-99.
38. MANN K, ACKERMANN K. Die OCDS-G: Psychometrische Kennwerte der deutschen Version der Obsessive Compulsive Drinking Scale. Sucht 2000;2:90-100.
39. SCHOECHLIN C, ENGEL RR. Meta-analysis of pharmacotherapeutic trials. In: ZERNIG G, SARIA A, KURZ M, O'MALLEY SS, eds, Handbook of alcoholism, Boca Raton: CRC Press, 2000: 339-352.
40. KRANZLER HR, VAN KIRK J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001;25:1335-1341.
41. RUBIO G, JIMÉNEZ-ARRIERO MA, PONCE G, PALOMO T. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001;36:419-425.
42. STROMBERG MF, MACKLER SA, VOLPICELLI JR, O'BRIEN CP. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. Alcohol 2001;23:109-116.
43. HEYSER CJ, MOC K, KOOB GF. Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology 2003;28:1463-1471.
44. MASON BJ, GOODMAN AM, DIXON RM et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596-606.
45. O'MALLEY SS, CARROLL KM. Psychotherapeutic considerations in pharmacological trials. Alcohol Clin Exp Res 1996;20:17A-22A.